| P50 | author | Till Sprenger | Q40284023 |
| P2093 | author name string | Ludwig Kappos | |
| P2860 | cites work | Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring | Q28243804 |
| | Oral treatment for multiple sclerosis | Q28250892 |
| | Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 |
| | Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial | Q28278620 |
| | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial | Q30053056 |
| | Alemtuzumab vs. interferon beta-1a in early multiple sclerosis | Q33381736 |
| | Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial | Q33400373 |
| | Multiple sclerosis: new insights in pathogenesis and novel therapeutics. | Q37925826 |
| | Predicting Risk of Progressive Multifocal Leukoencephalopathy from Natalizumab | Q43843587 |
| | Natalizumab plus interferon beta-1a for relapsing multiple sclerosis | Q44825022 |
| | Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis | Q45814039 |
| | A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans | Q60062004 |
| | CAMPATH-1H in multiple sclerosis | Q61651700 |
| | Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort | Q63352440 |
| | Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials | Q81041550 |
| P433 | issue | 9856 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 1795-1797 | |
| P577 | publication date | 2012-11-02 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Alemtuzumab for multiple sclerosis: who and when to treat? | |
| P478 | volume | 380 | |